Login to Your Account



Ipsen Exits Santhera Agreement on Fipamezole

By Cormac Sheridan
BioWorld International Correspondent

Wednesday, January 25, 2012
Santhera Pharmaceuticals AG is looking for a new partner for its Parkinson's disease drug fipamezole after Ipsen SA returned its rights to the drug, which covered territories outside of North America and Japan.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription